Seeking Alpha

Mike Zaman's  Instablog

Mike Zaman
Send Message
  • InterCloud Systems (ICLD), Cadence Pharma (CADX), Innotrac (INOC), Radar Attractors 0 comments
    Nov 15, 2013 10:27 AM | about stocks: ICLD, MNK, INOC

    http://static.cdn-seekingalpha.com/uploads/2013/11/15/saupload_icld.jpg InterCloud Systems, Inc. (NASDAQ:ICLD)

    Shares of ICLD soared after the company reported strong performance in revenue on its financial results compared with last year, attributable to organic growth and the acquisitions closed during the past year.

    For the third quarter 2013, ICLD posted revenue of $16.2 million, a 448% increase year over year, gross profit of $5.5 million, compared to $1.2 million in the same period the prior year, and net income of $1.3 million, or $0.26 basic earnings per share, and $0.12 diluted earnings per share, compared to a net loss of $0.8 million, or ($2.16) per share, in the third quarter of 2012.

    http://static.cdn-seekingalpha.com/uploads/2013/11/15/saupload_icld_chart2.png

    ICLD is a global single-source provider of value-added IT and telecom solutions for both corporate enterprises and service providers.

    More about InterCloud Systems, Inc. (ICLD) at www.intercloudsys.com.

    **

    http://static.cdn-seekingalpha.com/uploads/2013/11/15/saupload_cadx.jpg Cadence Pharmaceuticals, Inc. (CADX)

    According to the company, the U.S. District Court for the District of Delaware has ruled in favor of CADX in its patent infringement lawsuit against Exela Pharma Sciences, LLC.

    In August 2011, CADX and SCR Pharmatop, the patent owner, filed suit against Exela for infringement of two patents covering OFIRMEV(NYSE:R) (Acetaminophen) Injection, U.S. 6,028,222, which expires on August 5, 2017 (or February 5, 2018, if pediatric exclusivity is granted), and U.S. 6,992,218, which expires on June 6, 2021 (or December 6, 2021, if pediatric exclusivity is granted).

    The Court rejected Exela's claims that these patents are invalid and found that Exela's ANDA for a generic version of the product infringes both of these patents.

    CADX 's OFIRMEV (acetaminophen) Injection is indicated for the management of mild to moderate pain; the management of moderate to severe pain with adjunctive-opioid analgesics; and the reduction of fever.

    http://static.cdn-seekingalpha.com/uploads/2013/11/15/saupload_cadx_chart2.png

    CADX is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.

    More about Cadence Pharmaceuticals, Inc. (CADX) at www.cadencepharm.com

    **

    http://static.cdn-seekingalpha.com/uploads/2012/11/14/saupload_inoc.jpgInnotrac Corp. (NASDAQ:INOC)

    INOC stock surged after the company reported that it has entered into a definitive merger agreement with an affiliate of Sterling Partners, providing for the acquisition of all of the outstanding shares of Innotrac for $8.20 per share in cash.

    For the third quarter 2013, INOC posted total revenues of $29.8 million, a 15.8% increase year over year, and net income of $18.5 million, or $1.39 per share, fully diluted, compared to $1.1 million, or $0.08 per share, in the same period the prior year

    Under the terms of the merger agreement, an affiliate of Sterling Partners will promptly commence a tender offer for all of the outstanding shares of INOC. The agreement provides that, promptly after the closing of the tender offer, any shares not tendered in the tender offer will be acquired in a second-step merger at the same cash price as paid in the tender offer.

    http://static.cdn-seekingalpha.com/uploads/2013/11/15/saupload_inoc_chart21.png

    INOC is a best-in-class commerce provider integrating digital technology, fulfillment, contact center and business intelligence solutions to support global brands.

    More about Innotrac Corp. (INOC) at www.innotrac.com

    **

    Read Full Disclaimer at www.pennyomega.com/disclaimer

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Back To Mike Zaman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.